We had a brief thread here a few weeks ago.

The big difference between Horizant and regular gabapentin in my mind is the alleged increased bioavailability (rather than the timed-release aspect). It's still gabapentin, so I don't know that comparison with Lyrica would be any different.

I think the whole idea was to squeeze another patent or 3 out of what is now a generic medication. As Lyrica approaches patent expiration, I won't be surprised if they suddenly announce new timed release and more bioavailable versions of that (as well as some new 3G medication).

Doc